Oramed Pharmaceuticals (NASDAQ:ORMP – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a report issued on Thursday. A number of other research firms have also recently commented on ORMP. Cantor Fitzgerald initiated coverage on Oramed Pharmaceuticals in a research report on Friday, February 18th. They set an “overweight” […]
Brokerages predict that Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) will report earnings of ($0.19) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Oramed Pharmaceuticals’ earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.23). Oramed Pharmaceuticals reported earnings of ($0.17) per share during […]
Wall Street analysts forecast that Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) will announce $700,000.00 in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Oramed Pharmaceuticals’ earnings. Oramed Pharmaceuticals posted sales of $670,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 4.5%. […]